T
TNDM icon

Transce3nd’s Tandem Diabetes Care TNDM Stock Holding History

Transce3nd’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40
Closed -$1.44K – 1558
2024
Q4 		$1.44K Buy
+40
New +$1.35K ﹤0.01% 1150

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Transce3nd's TNDM Position: Q1 2025 in Review

Transce3nd sold out of Tandem Diabetes Care (TNDM) in Q1 2025, closing a stake of 40 shares — an estimated $1.44K sold.

Transce3nd first reported a position in TNDM in Q4 2024 and held it in 1 quarter. The position peaked at $1.44K in Q4 2024. 275 funds tracked by Wall St. Rank hold TNDM as of Q1 2025.

  • Transce3nd reported no remaining Tandem Diabetes Care position as of Q1 2025 after selling out during the quarter.
  • Transce3nd sold 40 Tandem Diabetes Care shares in Q1 2025, an estimated $1.44K.
  • Transce3nd first reported a position in Tandem Diabetes Care in Q4 2024 and held it in 1 quarter.
  • Transce3nd's Tandem Diabetes Care position peaked at $1.44K in Q4 2024.
  • 275 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2025.

Based on Transce3nd's 13F filing for Q1 2025, filed 5 May 2025.